Do elevated ALT and triglycerides indicate MASLD and hepatic insulin resistance?

The combined elevation of alanine aminotransferase (ALT) and triglycerides is a hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic insulin resistance. In this clinical profile, the liver becomes a driver of dyslipidemia through complex molecular shifts that prioritize lipid production over metabolic control.

Clinical and effectiveness evidence

In the context of MASLD (formerly NAFLD), elevated serum triglycerides (>150 mg/dL) serve as a core diagnostic criterion for the metabolic component of the disease. While ALT is not required for diagnosis, it is a primary clinical indicator of hepatocyte stress and injury.

• MASLD Identification: Guidelines from the European Association for the Study of the Liver (EASL) emphasize using triglycerides and liver enzymes like ALT to initiate screening for hepatic steatosis.
• Predictive Value: Composite indices that combine triglycerides and ALT, such as the TyG-ALT index, show high sensitivity (often with AUCs > 0.80) for identifying individuals with significant hepatic insulin resistance and fatty liver disease.
• Patient Context: For postmenopausal females, the loss of estrogen’s protective effect on lipid metabolism can exacerbate these markers, making the combination of high ALT and triglycerides particularly indicative of metabolic shifts in the liver.

Mechanistic explanations

The link between these markers and hepatic insulin resistance is rooted in "selective" insulin resistance, where the liver fails to regulate glucose production but continues to synthesize lipids.

• VLDL Overproduction: In a healthy state, insulin signaling via the IRS-PI3K-AKT pathway inhibits the assembly of Very-Low-Density Lipoprotein (VLDL). Specifically, AKT phosphorylates the transcription factor FOXO1, preventing it from upregulating microsomal triglyceride transfer protein (MTP), the enzyme responsible for packaging triglycerides into VLDL.
• Failed Suppression: In an insulin-resistant state, FOXO1 remains in the nucleus, leading to uncontrolled MTP expression and increased VLDL secretion.
• De Novo Lipogenesis: Despite general insulin resistance, the SREBP-1c pathway often remains active, driving the synthesis of new fats (lipogenesis). This provides an abundant supply of triglycerides to be packaged into VLDL, resulting in the characteristic elevation of serum triglycerides.
• Hepatocyte Injury (ALT): The accumulation of these intrahepatic lipids (steatosis) triggers oxidative stress and inflammatory pathways (such as JNK1 and PKC-δ), which damage hepatocyte membranes and cause ALT to leak into the bloodstream.

Bottom line

The simultaneous elevation of ALT and triglycerides strongly indicates hepatic insulin resistance and MASLD. This state is characterized by the liver’s inability to suppress VLDL production despite high circulating insulin, leading to a cycle of lipid overproduction and progressive liver stress.